Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride

Journal of Psychiatry and Neuroscience

Volumn 22, Issue 4, 1997, Pages 244-248

  Awad, A George ^a,e   Lapierre, Yvon D ^b   Angus, Carmella ^c   Rylander, Anders ^d   Saxena, D M ^f   Jones, B ^f   Williamson, P ^f   Vincent, P ^f   Carle, R ^f   Lavalle, Y J ^f   Manchanda, R ^f   Gauthier, B ^f   Wolf, M A ^f   Teehan, M D ^f   Dennis, J F ^f   Malla, A K ^f   Oyewumi, L K ^f   Busse, E ^f   Labelle, A ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c Astra Pharma Inc   (Canada)

^d Astra Arcus AB   (Sweden)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f NONE

Author keywords

Haloperidol; Negative symptoms; Quality of life; Remoxipride; Schizophrenia; Sickness Impact Profile

Indexed keywords

HALOPERIDOL; REMOXIPRIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEALTH STATUS; HOSPITALIZATION; HUMAN; MULTICENTER STUDY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; REMOXIPRIDE; SCHIZOPHRENIA;

EID: 8544259563     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Awad AG. 1992. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 43:262-5.
2. Awad AG. 1995. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington (DC): American Psychiatric Press, p 35-47.
3. Awad AG, Voruganti LNP, Heslegrave RJ. 1995. The aims of antipsychotic medication - what are they and are they being achieved? CNS Drugs 4:8-16.
4. Awad AG, Voruganti LNP, Heslegrave RJ. 1997a. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 11:32-47.
5. Awad AG, Voruganti LNP, Heslegrave RJ. 1997b. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 6:1-6.
6. Bergner M, Bobbit RA, Pollard W, Martin D, Gilson B. 1976. The Sickness Impact Profile: validation of a health status measure. Med Care 14:56-67.
7. Kuritz SJ, Landis JR, Koch CG. 1988. A general overview of Mantel-Haenszel methods: application and recent developments. Annu Rev Public Health 9:123-60.
8. Lapierre YD, Nair NPV, Awad AG, Chouinard G, Saxena B, Jones B, McClure DJ, Bakish D, Max P, Manchanda R, and others. 1990. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia: a Canadian multi-centre trial. Acta Psychiatr Scand 82 Suppl 358:78S-82S.
9. Lapierre YD, Ancill R, Awad G, Bakish D, Beaudry P, Bloom D, and others. 1992. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci 17:135-45.
10. Lapierre YD, Angus C, Awad AG, and the Canadian Remoxipride Study Group. The treatment of negative symptoms: a clinical and methodological study. Forthcoming.
11. Lewander T, Westerberg SE, Morrison D. 1990. Clinical profile of remoxipride - a combined analysis of a comparative double-blind multi-centre trial programme. Acta Psychiatr Scand 82 Suppl 358:92S-98S.
12. Ogren SO, Florvall L, Hall H, Magnusson O, Angelsy-Moller K. 1990. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 82 Suppl 358:21S-26S.
13. Revicki DA, Luce BR. 1995. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 31:57-65.
14. Romney DM. 1995. Psychosocial functioning and subjective experience in schizophrenia: a re-analysis. Schizophr Bull 21:405-10.
15. Voruganti LNP. 1996. Quality of life measurement in schizophrenia: a study of the credibility of patients' reports of self-rated quality of life [dissertation]. Toronto: Toronto Institute of Medical Science; 96 p. Available from: Institute of Medical Science Library, University of Toronto, Toronto, Ontario.
16. Voruganti LNP, Heslegrave RJ, Awad AG. 1995. Sickness Impact Profile (SIP) as a measure of patients' quality of life in clinical trials involving antipsychotic drugs [abstract]. In: 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11-15; San Juan, Puerto Rico, p 137.